I agree that this site is using cookies. You can find further informations here.
X
Azad, Arun
239  results:
Search for persons X
?
1

Precision medicine for prostate cancer: An international pe..:

Hamid, Anis A. ; Sweeney, Christopher J. ; Hovens, Christopher..
Urologic Oncology: Seminars and Original Investigations.  , 2024
Link: https://doi.org/10.1016/..
 
?
2

Role of FDG PET/CT in Management of Patients with Prostate ..:

Sutherland, Duncan E.K. ; Azad, Arun A. ; Murphy, Declan G....
Seminars in Nuclear Medicine.  54 (2024)  1 - p. 4-13 , 2024
Link: https://doi.org/10.1053/..
 
?
3

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel..:

Hofman, Michael S ; Emmett, Louise ; Sandhu, Shahneen...
The Lancet Oncology.  25 (2024)  1 - p. 99-107 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Publisher Correction: First-line talazoparib with enzalutam..:

Fizazi, Karim ; Azad, Arun A. ; Matsubara, Nobuaki...
Nature Medicine.  30 (2024)  5 - p. 1505-1505 , 2024
Link: https://doi.org/10.1038/..
 
?
5

Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatec..:

Eapen, Renu S. ; Buteau, James P. ; Jackson, Price...
European Urology.  85 (2024)  3 - p. 217-226 , 2024
Link: https://doi.org/10.1016/..
 
?
6

BRCA-deficient metastatic prostate cancer has an adverse pr..:

Fettke, Heidi ; Dai, Chao ; Kwan, Edmond M....
eBioMedicine.  95 (2023)  - p. 104738 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Emergence of triplet therapy for metastatic castration-sens..:

Sathianathen, Niranjan J. ; Pan, Henry Y.C. ; Lawrentschuk, Nathan...
Urologic Oncology: Seminars and Original Investigations.  41 (2023)  5 - p. 233-239 , 2023
Link: https://doi.org/10.1016/..
 
?
8

Is genetic testing coming of age in advanced prostate cance..:

Chen, Kenneth ; Ong, Sean ; Vasundhara, Kandarpa...
BJU International.  132 (2023)  5 - p. 496-498 , 2023
Link: https://doi.org/10.1111/..
 
?
9

NeoAdjuvant pembrolizumab and STEreotactic radiotherapy pri..:

Ali, Muhammad ; Wood, Simon ; Pryor, David...
Contemporary Clinical Trials Communications.  33 (2023)  - p. 101145 , 2023
Link: https://doi.org/10.1016/..
 
?
10

Determinants of outcome following PSMA-based radioligand th..:

Kostos, Louise ; Buteau, James P. ; Hofman, Michael S..
Therapeutic Advances in Medical Oncology.  15 (2023)  - p. 175883592311793 , 2023
Link: https://doi.org/10.1177/..
 
?
11

Talazoparib plus enzalutamide in men with first-line metast..:

Agarwal, Neeraj ; Azad, Arun A ; Carles, Joan...
The Lancet.  402 (2023)  10398 - p. 291-303 , 2023
Link: https://doi.org/10.1016/..
 
?
12

Treatment patterns and outcomes in older adults with castra..:

Fernando, Michael ; Anton, Angelyn ; Weickhardt, Andrew...
Journal of Geriatric Oncology.  14 (2023)  8 - p. 101621 , 2023
Link: https://doi.org/10.1016/..
 
?
13

PCPro: a clinically accessible, circulating lipid biomarker..:

Scheinberg, Tahlia ; Lin, Hui-Ming ; Fitzpatrick, Michael...
Prostate Cancer and Prostatic Diseases.  27 (2023)  1 - p. 136-143 , 2023
Link: https://doi.org/10.1038/..
 
?
14

Safety of Lutetium-177 prostate-specific membrane antigen-6..:

Sutherland, Duncan E. K. ; Kashyap, Raghava ; Jackson, Price...
Therapeutic Advances in Medical Oncology.  15 (2023)  - p. 175883592311770 , 2023
Link: https://doi.org/10.1177/..
 
?
15

First-line talazoparib with enzalutamide in HRR-deficient m..:

Fizazi, Karim ; Azad, Arun A. ; Matsubara, Nobuaki...
Nature Medicine.  30 (2023)  1 - p. 257-264 , 2023
Link: https://doi.org/10.1038/..
 
1-15